LEO Pharma

LEO Pharma submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China27.9.2024 12:30:00 CEST | LEO PharmaPressemeddelelse

LEO Pharma is seeking to expand the availability of Enstilar® (LEO 90100) to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA). The NDA is supported by results from a phase 3 trial comparing the efficacy and safety of Enstilar with Daivobet® ointment in adult Chinese patients.(1,2) The Enstilar submission demonstrates LEO Pharma's commitment to providing additional treatment options for the estimated seven million adult patients living with plaque psoriasis in China.(3)
PwC

190 nordjyske skoleelever fik testet deres evner i privatøkonomi27.9.2024 11:18:06 CEST | PwCPressemeddelelse

PwC i Aalborg mødte i denne uge ca. 190 elever fra lokale folkeskoler, der deltog i afsluttende kickout-events efter et fire-ugers undervisningsforløb i ’Ung privatøkonomi’. Eleverne blev gennem et specialudviklet spil udfordret i at anvende deres nyerhvervede viden om privatøkonomi og skulle træffe økonomiske beslutninger i realistiske dilemmaer, hvor de samtidig kunne vise personligt lederskab.
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
HiddenA line styled icon from Orion Icon Library.Eye